Inclusion Body Myositis Market
Global Inclusion Body Myositis Market Size, Share, and Trends, By Type (ACE-083, Aceneuramic Acid ER, ALZ-1903, UX-001P, UX-007, and Others), By End-User (Hospital, Clinic, and Others), Forecast (2022-2028) Update Available - Forecast 2024-2030
The global inclusion body myositis (IBM) market is expected to grow at a significant CAGR during the forecast period (2022-2028). Muscle weakness and damage are caused by inclusion body myositis, which is a rare condition. Progressive weakness in the muscles of the hand, forearm, thigh, and lower leg are among the symptoms of IBM; however, the symptoms vary and are not unique to this condition. Furthermore, it is estimated to be 51-139 per 1,000,000 people over the age of 50 in the general population. As a result, IBM is the most common acquired muscle disorder in people over the age of 50. And its increasing prevalence and awareness about the treatments is expected to surge the market growth.
Impact of COVID-19 Pandemic on Global Inclusion Body Myositis Market
The COVID-19 pandemic had positively impacted the global inclusion body myositis market. COVID-19 is associated with a viral myositis attributable to direct myocyte invasion or induction of autoimmunity. COVID-19-induced myositis may be varied in presentation, from typical dermatomyositis to rhabdomyolysis, and a paraspinal affliction with back pain. A study performed in patients with COVID-19 reported that about 13.7% of these patients had elevated CK levels. Muscle weakness related to COVID-19 has been reported in patients having covid symptoms. .
Segmental Outlook
The global inclusion body myositis market is segmented based on type and application. Based on the type, the market is segmented into ACE-083, Aceneuramic Acid ER, ALZ-1903, UX-001P, UX-007. Based on the application, the market is sub-segmented into the hospital, clinic. Based on type, ACE-083, Aceneuramic Acid ER, ALZ-1903, UX-001P, UX-007 inclusion body myositis is expected to hold major share in the market.
Global Inclusion Body Myositis Market Share by Application, 2021 (%)
The HospitalSegment Holds the Prominent Shares in the Global Inclusion Body Myositis Market
The hospital segment is likely to hold significant share in the market during the forecast period. The increasing healthcare expenditure globally is the major factors that hospital infrastructure has become well developed with associated medical facilities. In 2019, the U.S. spent $5.35million 9 on domestic general government healthcare, up from $3.51 in 2019. Apart from this, the healthcare expenditure in the UK accounted for 10.2% of gross domestic product (GDP) in 2019, compared with 9.9% in 2018.
Regional Outlooks
The global inclusion body myositis market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). Among the regions, the Asia-Pacific is anticipated to hold a significant share in the market followed by North America, and then Europe.
Global Inclusion Body Myositis Market Growth, by Region 2022-2028
The Asia-Pacific Region Expected to Hold Considerable Share in the Global Inclusion Body Myositis Market
Asia-Pacific region holds the major share and is anticipated to grow fastest during the forecast period in the inclusion body myositis market. The Asia Pacific market is expected to grow significantly over the forecast period, owing to the high prevalence of musculoskeletal diseases in the region, as well as a large geriatric population. According to a WHO report, more than 369 million people in Southeast Asia suffer from muscle-related diseases. Because of high health awareness among the population and easy access to quality healthcare in developed countries, the market in Asia-Pacific is expected to gain the largest market share over the forecast period.
Market Players Outlook
The major companies serving the global inclusion body myositis market include Acceleron Pharma Inc., Abcuro, Gradalis, Inc., KPI Therapeutics Inc., Milo Biotechnology LLC, Novartis AG, Ultragenyx Pharmaceutical Inc., and others. . To remain competitive in the market, market players are adopting various strategies such as mergers and acquisitions, geographical expansion, partnerships and collaborations, and new product launches, which contribute significantly to market growth. For example, Abcuro announced in January 2021 that it had raised $42 million in a Sanofi Ventures-led series A to advance anti-KLRG1 treatments for autoimmune diseases and cancers. The funding was intended to be used to conduct a proof-of-mechanism clinical trial in patients with sporadic inclusion body myositis (IBM).
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global inclusion body myositis market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Inclusion Body Myositis Industry
• Recovery Scenario of Global Inclusion Body Myositis Industry
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Trade Analysis
2.2.3. Porter’s Analysis
2.2.4. Recommendations
2.2.5. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on key players
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Inclusion Body Myositis Market, By Type
5.1.1. ACE-083
5.1.2. Aceneuramic Acid ER
5.1.3. ALZ-1903
5.1.4. UX-001P
5.1.5. UX-007
5.1.6. Others
5.2. Global Inclusion Body Myositis Market, By End-User
5.2.1. Hospital
5.2.2. Clinic
5.2.3. Others
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. South Korea
6.3.5. Rest of Asia-Pacific
6.4. Rest of the World
6.4.1. Latin America
6.4.2. Middle East & Africa
7. Company Profiles
7.1. Acceleron Pharma Inc
7.2. Gradalis, Inc.
7.3. KPI Therapeutics Inc
7.4. Milo Biotechnology LLC
7.5. New Zealand Pharmaceuticals Ltd,
7.6. Nobelpharma Co Ltd
7.7. Novartis AG
7.8. Orphazyme ApS
7.9. Ultragenyx Pharmaceutical Inc
1. GLOBAL INCLUSION BODY MYOSITIS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL ACE-083 INCLUSION BODY MYOSITIS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL ACENEURAMIC ACID ER INCLUSION BODY MYOSITIS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL ALZ-1903 INCLUSION BODY MYOSITIS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL UX-001P INCLUSION BODY MYOSITIS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL UX-007 INCLUSION BODY MYOSITIS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL OTHER INCLUSION BODY MYOSITIS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL INCLUSION BODY MYOSITIS MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
9. GLOBAL INCLUSION BODY MYOSITIS IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL INCLUSION BODY MYOSITIS IN OTHER END-USER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL INCLUSION BODY MYOSITIS IN CLINICAL MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
12. NORTH AMERICAN INCLUSION BODY MYOSITIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
13. NORTH AMERICAN INCLUSION BODY MYOSITIS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
14. NORTH AMERICAN INCLUSION BODY MYOSITIS MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
15. EUROPEAN INCLUSION BODY MYOSITIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
16. EUROPEAN INCLUSION BODY MYOSITIS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
17. EUROPEAN INCLUSION BODY MYOSITIS MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
18. ASIA-PACIFIC INCLUSION BODY MYOSITIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
19. ASIA-PACIFIC INCLUSION BODY MYOSITIS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
20. ASIA-PACIFIC INCLUSION BODY MYOSITIS MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
21. REST OF THE WORLD INCLUSION BODY MYOSITIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
22. REST OF THE WORLD INCLUSION BODY MYOSITIS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
23. REST OF THE WORLD INCLUSION BODY MYOSITIS MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL INCLUSION BODY MYOSITIS MARKET, 2021-2028 (% MILLION)
2. IMPACT OF COVID-19 ON GLOBAL INCLUSION BODY MYOSITIS MARKET BY SEGMENT, 2021-2028 (% MILLION)
3. RECOVERY OF GLOBAL INCLUSION BODY MYOSITIS MARKET, 2021-2028 (%)
4. GLOBAL INCLUSION BODY MYOSITIS MARKET SHARE BY TYPE, 2020 VS 2027 (%)
5. GLOBAL INCLUSION BODY MYOSITIS MARKET SHARE BY END-USER, 2020 VS 2027 (%)
6. GLOBAL INCLUSION BODY MYOSITIS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
7. GLOBAL ACE-083 INCLUSION BODY MYOSITIS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
8. GLOBAL ACENEURAMIC ACID ER INCLUSION BODY MYOSITIS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
9. GLOBAL ALZ-1903 INCLUSION BODY MYOSITIS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
10. GLOBAL UX-001P INCLUSION BODY MYOSITIS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
11. GLOBAL UX-007 INCLUSION BODY MYOSITIS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
12. GLOBAL OTHER INCLUSION BODY MYOSITIS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
13. GLOBAL INCLUSION BODY MYOSITIS IN HOSPITAL MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
14. GLOBAL INCLUSION BODY MYOSITIS IN CLINIC MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
15. US INCLUSION BODY MYOSITIS MARKET SIZE, 2021-2028 ($ MILLION)
16. CANADA INCLUSION BODY MYOSITIS MARKET SIZE, 2021-2028 ($ MILLION)
17. UK INCLUSION BODY MYOSITIS MARKET SIZE, 2021-2028 ($ MILLION)
18. FRANCE INCLUSION BODY MYOSITIS MARKET SIZE, 2021-2028 ($ MILLION)
19. GERMANY INCLUSION BODY MYOSITIS MARKET SIZE, 2021-2028 ($ MILLION)
20. ITALY INCLUSION BODY MYOSITIS MARKET SIZE, 2021-2028 ($ MILLION)
21. SPAIN INCLUSION BODY MYOSITIS MARKET SIZE, 2021-2028 ($ MILLION)
22. REST OF EUROPE INCLUSION BODY MYOSITIS MARKET SIZE, 2021-2028 ($ MILLION)
23. INDIA INCLUSION BODY MYOSITIS MARKET SIZE, 2021-2028 ($ MILLION)
24. CHINA INCLUSION BODY MYOSITIS MARKET SIZE, 2021-2028 ($ MILLION)
25. JAPAN INCLUSION BODY MYOSITIS MARKET SIZE, 2021-2028 ($ MILLION)
26. SOUTH KOREA INCLUSION BODY MYOSITIS MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF ASIA-PACIFIC INCLUSION BODY MYOSITIS MARKET SIZE, 2021-2028 ($ MILLION)
28. REST OF THE WORLD INCLUSION BODY MYOSITIS MARKET SIZE, 2021-2027($ MILLION
